Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Papillomavirus Infections 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Hydronephrosis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

tremelimumab 1durvalumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Anatomic Stage II Breast Cancer AJCC v8 × durvalumab × Clear all
NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
16 enrolled 8 charts
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡